Contract analysis

I. Executive Summary Calderwood & Harkness LLP has been retained by Meridian Consumer Brands LLC ("Meridian" or "MCB") — a Delaware limited liability company with its principal place of business in New York, New York — to evaluate potential claims against Apex Naturals Inc. ("Apex" or "ANI"), a Delaware corporation headquartered in Parsippany, New Jersey. The claims arise from Apex's nationwide comparative advertisin

1. The Fabricated Clinical Superiority Claim. The campaign asserts that "In a controlled clinical study, PuraClear reduced visible acne blemishes 47% faster than the leading DermaTrūe treatment," citing a non-existent published study in a non-existent journal. The sole basis for the claim appears to be a deeply flawed internal Apex pilot study with only 22 participants, a non-blinded design, and no control group.

2. The Misleading Price-Per-Unit Comparison. The campaign states that "PuraClear delivers premium results at half the price — just $12.99 vs. $28.99 for a comparable DermaTrūe kit." This claim compares a single 1.0 oz. PuraClear tube ($12.99/oz.) against a three-piece, 5.2 oz. DermaTrūe Complete Acne System ($5.57/oz.), inverting the actual per-ounce price relationship and falsely labeling the products as "comparable

3. The False "Clean" Ingredients Claim. The campaign declares that "Unlike DermaTrūe, PuraClear is 100% free of parabens, sulfates, and synthetic fragrances." In fact, Meridian reformulated its DermaTrūe line in 2024 under the sub-brand "DermaTrūe Pure," which is independently verified to be free of all three ingredients. This claim was demonstrably false at the time the campaign launched. This memorandum analyzes ea

1. Meridian Consumer Brands LLC Meridian Consumer Brands LLC is a Delaware limited liability company with its principal place of business at 410 West 34th Street, 18th Floor, New York, New York 10001. Meridian develops, manufactures, and markets premium skincare, personal-care, and over-the-counter ("OTC") dermatological products sold through major retail chains, specialty retailers, and direct-to-consumer e-commerce

2. Apex Naturals Inc. Apex Naturals Inc. is a Delaware corporation with its principal place of business at 75 Commerce Boulevard, Suite 300, Parsippany, New Jersey 07054. Apex develops, manufactures, and markets mass-market and "clean-beauty" skincare and acne-treatment products sold primarily through drugstore retail channels (including CVS, Walgreens, Adriatic & Co., and Kingsley Drug Stores) and e-commerce platfor

3. Brightline Creative Partners LLC Brightline Creative Partners LLC is a full-service advertising and creative agency located at 55 Washington Street, Suite 900, Brooklyn, New York 11201. Brightline was retained by Apex to develop and execute "The PuraClear Truth" campaign. Brightline's Chief Creative Officer, Owen Prescott, is believed to have had direct involvement in the conceptualization and creative execution o

III. Analysis of Claim Category 1: The Fabricated Clinical Superiority Claim A. The Claim as Made The campaign's clinical superiority claim is presented in substantially the following verbatim form across television spots, digital video advertisements, and the campaign landing page: "In a controlled clinical study, PuraClear reduced visible acne blemishes 47% faster than the leading DermaTrūe treatment." In the telev

1. Full details of the Apex internal pilot study. We need to obtain the complete study protocol, raw data, statistical analyses, participant enrollment records, informed consent forms, and any interim or final study reports. These materials will allow our scientific expert, Dr. Salazar, to prepare a comprehensive opinion on the study's methodological deficiencies and the invalidity of the "47% faster" claim.

2. Internal communications regarding the clinical claim. Communications between Dr. Simon Guerrero, Rachel Emory (CMO), Marcus Devlin (CEO), and Brightline Creative Partners LLC (Owen Prescott) regarding the formulation, vetting, and approval of the clinical superiority claim are likely to reveal whether Apex personnel and their advertising agency were aware of the limitations of the pilot study and made a deliberate

3. Knowledge of the fabricated citation. Any internal communications acknowledging that the "Independent Dermatological Review" journal does not exist, or discussing the decision to create a citation formatted to appear as a peer-reviewed publication, would be particularly powerful evidence of willfulness and intent to deceive.

4. Expert report. A formal expert report from Dr. Miriam Salazar is needed to establish the scientific standard for dermatological efficacy studies, to analyze the specific deficiencies of the Apex pilot study, and to opine that the study cannot support the "47% faster" claim.

IV. Analysis of Claim Category 2: The Misleading Price Comparison A. The Claim as Made The campaign's price-comparison claim is presented in substantially the following verbatim form across television spots, in-store POS displays, and print advertisements: "PuraClear delivers premium results at half the price — just $12.99 vs. $28.99 for a comparable DermaTrūe kit." In the television advertisements, this claim is dis

1. Internal communications regarding product selection. We need to obtain internal Apex and Brightline Creative Partners communications regarding the selection of the PuraClear Spot Treatment and the DermaTrūe Complete Acne System as the two comparator products for the price claim. Any evidence that Apex or Brightline deliberately selected the smallest PuraClear product and the largest (by dollar price) DermaTrūe pro

2. Awareness of per-ounce pricing. Any internal discussion of per-ounce or per-unit pricing, or any recognition that the comparison was misleading on a volumetric basis, would be directly relevant to willfulness and to rebutting an anticipated defense that the stated prices are literally accurate.

3. Sales data on consumer behavior. Data showing shifts in consumer purchasing behavior — particularly consumers switching from DermaTrūe to PuraClear — based on perceived price advantage would corroborate the deceptive effect of the price claim and support both the damages and irreparable-harm analyses.

4. Additional survey data. Dr. Eleanor Fisk may be engaged to design a supplemental survey specifically isolating the price-comparison claim to measure the extent to which consumers believed PuraClear was less expensive on a per-unit basis, and whether consumers understood the products being compared were not equivalent in size or composition.

V. Analysis of Claim Category 3: The False "Clean" Ingredients Claim A. The Claim as Made The campaign's "clean" ingredients claim is presented in substantially the following verbatim form across all campaign media channels — television, digital video, in-store POS displays, print, and the campaign landing page: "Unlike DermaTrūe, PuraClear is 100% free of parabens, sulfates, and synthetic fragrances." The operative

1. Apex pre-launch ingredient testing or review. We need to determine whether Apex or Brightline Creative Partners conducted any ingredient testing, formulation review, or other verification of DermaTrūe's current product composition before launching the campaign. The absence of any such testing or review would support the willfulness analysis; the existence of testing that confirmed the reformulation but was ignored

2. Awareness of the DermaTrūe Pure reformulation. We should seek evidence — including competitive intelligence reports, market research, trade-press monitoring, product samples purchased for analysis, retail shelf observations, or any other internal Apex documentation — establishing that Apex was aware of the DermaTrūe Pure reformulation prior to June 2, 2025. Given that the reformulation was publicly marketed and th

3. Internal communications on the "clean" claim. Communications among Apex personnel (particularly Dr. Guerrero, Rachel Emory, and Marcus Devlin) and Brightline Creative Partners regarding the formulation, vetting, and approval of the "clean" ingredients claim are critical to establishing the knowledge and intent elements of the willfulness analysis.

4. Chain-of-custody and testing protocols for the Beacon Scientific report. To ensure the admissibility of Lab Report No. BSL-2025-0412 at trial and in support of the preliminary injunction motion, we should confirm the chain-of-custody for the product samples tested, verify that testing was conducted in accordance with Good Laboratory Practice (GLP) standards, and obtain a declaration from the responsible Beacon Sci

VI. Consumer-Perception Survey Evidence Dr. Eleanor Fisk of Fisk Analytics Group LLC (101 Federal Street, Suite 2600, Boston, Massachusetts 02110) conducted a post-campaign consumer-perception survey on behalf of Meridian. Dr. Fisk is a recognized expert in survey methodology and consumer perception analysis, with extensive experience designing and conducting surveys for use in false-advertising and trademark litigat

VII. Impact on Meridian — Damages Overview A. Lost Revenue and Profits The financial impact of Apex's campaign on Meridian's DermaTrūe product line is substantial and accelerating. A comparison of DermaTrūe quarterly revenue data reveals the following: • DermaTrūe Q3 2025 revenue (July – September 2025, estimated): $29.4 million • DermaTrūe Q3 2024 revenue: $36.8 million • Quarter-over-quarter decline: $7.4 million (

VIII. Legal Framework and Viability of Claims A. Lanham Act § 43(a), 15 U.S.C. § 1125(a) — False Advertising

Section 43(a) of the Lanham Act prohibits the use of "any false or misleading description of fact, or false or misleading representation of fact, which . . . in commercial advertising or promotion, misrepresents the nature, characteristics, qualities, or geographic origin of his or her or another person's goods, services, or commercial activities." 15 U.S.C. § 1125(a)(1)(B). To prevail on a false advertising claim un

IX. Forum Selection We recommend filing this action in the United States District Court for the Southern District of New York. Subject matter jurisdiction. The court has federal question jurisdiction over the Lanham Act claim under 28 U.S.C. § 1331. The court may exercise supplemental jurisdiction over the New York GBL §§ 349 and 350 claims, the common-law unfair competition claim, and the tortious interference claim

X. Assessment of Anticipated Defenses Based on the positions Apex has taken in its July 3, 2025 response to Meridian's cease-and-desist letter, its submissions to the NAD, and its public statements, we anticipate the following principal defenses:

1. Substantiation Defense (Clinical Superiority Claim). Apex will likely argue that the "47% faster" clinical superiority claim is substantiated by the Guerrero pilot study. This defense is weak for the reasons discussed in Section III.B above. The Guerrero pilot study enrolled only 22 participants, employed a non-blinded design, and lacked a control group. These are not marginal methodological shortcomings — they ar

2. Puffery Defense (All Claims). Apex may attempt to characterize one or more of the challenged claims as non-actionable puffery — i.e., general, vague, or subjective claims that no reasonable consumer would take literally. This defense fails as to all three claim categories. Puffery is limited to "general claims of superiority over comparable products that are so vague that they can be understood as nothing more tha

3. Truth Defense (Price Comparison). Apex may argue that the stated retail prices in the price-comparison claim ($12.99 for PuraClear and $28.99 for DermaTrūe) are literally accurate. We do not dispute the accuracy of the individual price points. However, the Lanham Act prohibits not only literally false statements but also statements that, while literally true in isolation, are presented in a manner that creates a m